16590 studies found for:    "Vascular Diseases"
Show Display Options
Rank Status Study
21 Active, not recruiting Noninvasive Predictors of Transplant Vasculopathy
Condition: Cardiac Allograft Vasculopathy
Intervention:
22 Unknown  Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: Intravitreal Bevacizumab
23 Active, not recruiting Noninvasive Evaluation of Cardiac Allograft Vasculopathy
Condition: Cardiac Allograft Vasculopathy
Intervention:
24 Completed
Has Results
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc
25 Unknown  Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: ranibizumab 2.0mg
26 Active, not recruiting Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc
27 Completed
Has Results
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Interventions: Drug: Verteporfin Photodynamic Therapy;   Drug: Ranibizumab
28 Completed Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
Condition: Polypoidal Choroidal Vasculopathy
Intervention:
29 Completed Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia
Condition: Peripheral Vascular Diseases
Intervention: Device: VascuActive
30 Unknown  Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant
Conditions: Cardiac Allograft Vasculopathy;   Heart Transplant Recipients
Intervention:
31 Active, not recruiting Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
Conditions: PCV;   Polypoidal Choroidal Vasculopathy
Interventions: Drug: high-dose ranibizumab;   Drug: ranibizumab
32 Suspended Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
Condition: Cardiac Allograft Vasculopathy
Intervention: Drug: Sirolimus
33 Recruiting Open-label Pilot Study to Assess the Use of Magic Foot™ in the Improvment of Parameters in Subject With Foot Symptoms
Conditions: Diabetes;   Peripheral Vascular Disease
Intervention: Device: Magic Foot™
34 Completed Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
Condition: Polypoidal Choroidal Vasculopathy
Interventions: Drug: fosbretabulin;   Drug: Saline
35 Terminated Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia
Condition: Peripheral Vascular Disease
Interventions: Drug: Hemoglobin glutamer 250 - bovine;   Drug: 6% Hydroxyethylstarch
36 Recruiting The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.
Conditions: Cardiac Allograft Vasculopathy;   Cardiac Allograft Rejcetion;   Exercise Capacity HTX Patients;   Haemodynamic Changes During Exercise HTX Patients;   Right Heart Function HTX Patients
Interventions: Procedure: OCT and coronary angiography;   Procedure: Right heart cat.;   Radiation: PET;   Procedure: Echocardiography;   Procedure: exercise test;   Other: blood samples
37 Completed Vascular Risk Factors in INPH-patients
Conditions: Hydrocephalus, Normal Pressure;   Vascular Diseases;   Brain Diseases;   Central Nervous System Diseases;   Nervous System Diseases
Intervention:
38 Active, not recruiting Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
Conditions: Peripheral Arterial Disease;   Intermittent Claudication;   Vascular Diseases;   Cardiovascular Diseases
Intervention: Device: STANZA Drug-eluting resorbable Scaffold
39 Recruiting A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Conditions: Critical Limb Ischemia;   Vascular Diseases;   Peripheral Arterial Disease
Intervention: Genetic: HGF Plasmid
40 Completed Raynaud's Treatment Study (RTS)
Conditions: Cardiovascular Diseases;   Heart Diseases;   Raynaud's Disease;   Vascular Diseases
Interventions: Drug: nifedipine;   Behavioral: biofeedback (psychology);   Procedure: electromyography

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years